

1. MAP
2. MAP
- 3.

A

(A-a)

1. Ozaki, K., Kosugi, M., Baba, N., Fujio, K., Sakamoto, T., Kimura, S., Tanimura, S. & Kohno, M. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. *Biochem. Biophys. Res. Commun.*, 391, 1610-1615, 2010. (IF: 2.548)
2. Watanabe, K., Tanimura, S., Uchiyama, A., Sakamoto, T., Kawabata, T., Ozaki, K. & Kohno, M. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. *Clin. Cancer Res.*, 16, 1170-1178, 2010. (IF: 6.747) (Selected as a highlighted article)
3. Tamura, S., Hattori, Y., Kaneko, M., Shimizu, N., Tanimura, S., Kohno, M. & Murakami, N. Peumusolide A, unprecedented NES non-antagonistic inhibitor for nuclear export of MEK. *Tetrahedron Lett.*, 51, 1678-1681, 2010. (IF: 2.660)

B

(B-b)

1. K. Ozaki, K. Hyakutake, M. Kohno: PI3K-Akt pathway inhibitors enhance the cytotoxicity of microtubule-destabilizing agents via ceramide accumulation, 69
2. T. Sakamoto, K. Fujio, S. Kajikawa, S. Uesato, K. Watanabe, S. Tanimura, K. Ozaki, M. Kohno: Blockade of the ERK pathway enhances the therapeutic efficacy of HDAC inhibitors in human tumor xenograft models, 69
3. , , , , , , Myosin 1E invadopodia , 69
4. , , , , : ERK HDAC , 2010,
5. , , SH3P2 , 2010,

6. , , , , :
, BMB2010 33 83
7. , , , , , ,
SH3P2 , BMB2010 33
83 ,
8. , , , , MEK
, 27 ,
9. , , , , Myosin 1E
, 27 ,
10. , , , , ,
SH3P2 Myosin 1E , 27 ,
11. , , , : PI3K/Akt
, 27 ,
12. , , , , : HDAC MEK
FOXO , 27
,

ERK-MAP

(B)

;

- 1.
- 2.

80	0
1	22
2	10
0	5
3	